Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome - PubMed (original) (raw)
. 2006 Mar 1;106(5):1090-8.
doi: 10.1002/cncr.21723.
Affiliations
- PMID: 16435386
- DOI: 10.1002/cncr.21723
Free article
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome
Hagop Kantarjian et al. Cancer. 2006.
Free article
Abstract
Background: Elderly patients (age > or = 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML-type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and oncologists advocate, at times, only supportive care or frontline single agents, Phase I-II studies, low-intensity regimens, or 'targeted' therapies. However, baseline expectations for outcomes of elderly AML with 'standard' AML-type therapy are not well defined. The aim was to develop prognostic models for complete response (CR), induction (8-week) mortality, and survival rates in elderly AML, which would be used to advise oncologists and patients of expectations with standard AML type therapy, and to establish baseline therapy results against which novel strategies would be evaluated.
Methods: A total of 998 patients age > or = 65 years with AML or high-risk myelodysplastic syndrome (> 10% blasts) treated with intensive chemotherapy between 1980 and 2004 were analyzed. Univariate and multivariate analyses of prognostic factors associated with CR, induction (8-week) mortality, and survival used standard methods.
Results: The overall CR rate was 45% and induction mortality 29%. Multivariate analysis of prognostic factors identified consistent independent poor prognostic factors for CR, 8-week mortality, and survival. These included age > or = 75 years, unfavorable karyotypes (often complex), poor performance (3-4 ECOG [Eastern Cooperative Oncology Group]), longer duration of antecedent hematologic disorder, treatment outside the laminar airflow room, and abnormal organ functions. Patients could be divided into: 1) a favorable group (about 20% of patients) with expected CR rates above 60%, induction mortality rates of 10%, and 1-year survival rates above 50%; 2) an intermediate group (about 50-55% of patients) with expected CR rates of 50%, induction mortality rates of 30%, and 1-year survival rates of 30%; and 3) an unfavorable risk group (about 25-30% of patients) with expected CR rates of less than 20%, induction mortality rates above 50%, and 1-year survival rates of less than 10%.
Conclusions: Prognostic models, based on standard readily available baseline characteristics, were developed for elderly patients with AML, which may assist in therapeutic and investigational decisions. These predictive models, based on a retrospective analysis, will require validation in independent study groups.
Similar articles
- The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Chen Y, Yang T, Zheng X, Yang X, Zheng Z, Zheng J, Liu T, Hu J. Chen Y, et al. Medicine (Baltimore). 2016 Jul;95(30):e4182. doi: 10.1097/MD.0000000000004182. Medicine (Baltimore). 2016. PMID: 27472687 Free PMC article. - The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, Isidori A, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S. Visani G, et al. Leukemia. 2001 Jun;15(6):903-9. doi: 10.1038/sj.leu.2402142. Leukemia. 2001. PMID: 11417475 Review. - Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Sasaki K, et al. Cancer. 2023 Apr 1;129(7):1017-1029. doi: 10.1002/cncr.34609. Epub 2023 Jan 30. Cancer. 2023. PMID: 36715486 - A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care. Kimby E, et al. Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321. Acta Oncol. 2001. PMID: 11441935 Review.
Cited by
- Current status and research directions in acute myeloid leukemia.
Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, Kadia T, Sasaki K, Short NJ, Yilmaz M, Ravandi F. Kantarjian H, et al. Blood Cancer J. 2024 Sep 19;14(1):163. doi: 10.1038/s41408-024-01143-2. Blood Cancer J. 2024. PMID: 39300079 Free PMC article. Review. - Evaluate the Efficacy of Myeloablative Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myelogenous Leukemia at BTH, Vietnam.
Nguyen TH, Huynh HT, Tran HQ, Nguyen QT, Huynh PDV, Hoang ND, Ma TX, Thuy Do DT, Phu DC, Huynh MV. Nguyen TH, et al. Int J Hematol Oncol Stem Cell Res. 2024 Jul 1;18(3):254-261. doi: 10.18502/ijhoscr.v18i3.16106. Int J Hematol Oncol Stem Cell Res. 2024. PMID: 39257712 Free PMC article. - Ferroptosis-Related Gene Signature for Prognosis Prediction in Acute Myeloid Leukemia and Potential Therapeutic Options.
Hong Y, Liu Q, Xin C, Hu H, Zhuang Z, Ge H, Shen Y, Zhao Y, Zhou Y, Ye B, Wu D. Hong Y, et al. Int J Gen Med. 2024 Sep 4;17:3837-3853. doi: 10.2147/IJGM.S460164. eCollection 2024. Int J Gen Med. 2024. PMID: 39246807 Free PMC article. - The changing landscape of geriatric care in acute myeloid leukemia: a 5-year analysis of inpatient mortality predictors, trends in mortality, and chemotherapy use.
Bodla ZH, Hashmi M, Niaz F, Khalil MJ, Khalid F, Niaz Z, Hashmi MA, Farooq U, Chaudhury R, Bray CL. Bodla ZH, et al. Proc (Bayl Univ Med Cent). 2024 Jul 29;37(5):813-821. doi: 10.1080/08998280.2024.2381174. eCollection 2024. Proc (Bayl Univ Med Cent). 2024. PMID: 39165800 Free PMC article. - Serum albumin is associated with the inherent property of acute myeloid leukemia and correlates with patient outcomes.
Chen J, Hui Y, Zhai Y, Yang M, Zhang X, Mi Y, Wang J, Wei H. Chen J, et al. Blood Sci. 2024 May 10;6(2):e00189. doi: 10.1097/BS9.0000000000000189. eCollection 2024 Apr. Blood Sci. 2024. PMID: 38742239 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical